Article info
PDFClinical science
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment
- Correspondence to Dr Yoav Nahum, Ophthalmology, Rabin Medical Center, Petah Tikva, Israel; yoav.nahum{at}gmail.com
Citation
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment
Publication history
- Received July 30, 2019
- Revised September 6, 2019
- Accepted September 13, 2019
- First published September 25, 2019.
Online issue publication
May 04, 2023
Article Versions
- Previous version (21 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.